11-6-13 4:05 PM EST | Email Article

- Conference Call and Webcast Today at 4:30 p.m. ET -

NEW YORK, Nov. 6, 2013 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational developments for the fiscal third quarter and nine months ended September 30, 2013. Developments for the quarter and recent weeks subsequent to quarter end are as follows:

  • Finalizing plans to initiate a global Phase 2 efficacy and safety study to investigate its Melphalan Hepatic Delivery System (Melphalan HDS) for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC); the U.S. Food & Drug Administration (FDA) granted the Company orphan drug designation for melphalan in the treatment of patients with HCC
  • The Company raised approximately $7.5 million in gross proceeds in an offering of shares of its common stock and warrants to purchase common stock; cash and cash equivalents as of September 30, 2013 were $27.7 million; combined with October financing activities, pro forma cash and cash equivalents were approximately $35 million
  • The Company completed a reorganization of its operations, reducing headcount by a further 33% and lowering its cash utilization by more than 50% compared to the same quarter in the prior year; the Company expects to reduce operating costs in 2014 by approximately $10 million compared to 2013, while focusing resources on its clinical development program
  • The Company's Board of Directors appointed Jennifer K. Simpson and Graham G. Miao as Interim Co-Presidents and Co-CEOs following the separation of Eamonn P. Hobbs from the Company; a Transition Committee was formed to assist the Board and senior management in implementing a leadership transition plan and its evaluation of potential strategic alternatives for the Company
  • Delcath received a complete response letter (CRL) from the U.S. Food & Drug Administration (FDA)  regarding  the non-approval of the Company's New Drug Application (NDA) for Delcath's MelblezTM Kit (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System) for the treatment of patients with unresectable ocular melanoma metastatic to the liver;  the Company is evaluating the requirements contained in the letter, and will review potential regulatory paths forward with the FDA for the indication of ocular melanoma liver metastasis

"The actions we took this quarter were designed to optimize utilization of available resources on continued CHEMOSAT clinical adoption in Europe and our clinical development program for HCC," commented Jennifer Simpson, Interim Co-President and Co-CEO. "We are currently pursuing a focused market access approach in Europe by seeking interim reimbursement mechanisms for CHEMOSAT procedures in Germany and the United Kingdom, where adoption of CHEMOSAT has been strongest. In addition, we continue to evaluate various interim reimbursement pathways in other target countries in the EU. We believe these mechanisms will help build the foundation for commercialization and help support long-term revenue growth."

"In looking at the HCC market, we believe our greatest potential opportunity is in the first line setting," continued Dr. Simpson. "As a result, we have modified our proposed clinical trial accordingly, and will be seeking comments from the FDA. Subject to agreement by the FDA, we now anticipate enrolling our first patient in our HCC Phase 2 trial in the first quarter of 2014."

Financial Results

For the third quarter ended September 30, 2013, total revenue was $72,000 compared with total revenue of $39,000 in the in third quarter 2012.  Operating expenses decreased by approximately 44% to $6.8 million from $12.2 million for the same period in 2012. The decrease is primarily due to a significant reduction in expenses related to the Company's NDA submission to the FDA, as well as the Company's overall cost management efforts. Operating loss was $6.7 million, which included non-cash stock-based compensation income of $0.2 million, as compared with an operating loss of $12.2 million, including $1.1 million in non-cash stock-based compensation expense, in the year ago period.

"During the quarter, the proactive decisions we made have enabled our organization to be more efficient and lowered our cash utilization by 53% compared to the prior year period. We expect that these actions will reduce annual operating costs by approximately $10 million while preserving our ability to invest in our clinical strategy," commented Graham Miao, Interim Co-President and Co- CEO. "With our current cash balance, buoyed with the just completed capital raise, we have strengthened our balance sheet, which we believe will allow us to execute our strategy into 2015."

For the nine months ended September 30, 2013, total revenue was approximately $452,000, of which $300,000 was related to the recognition of previously deferred revenue. Total operating expenses for the nine months ended September 30, 2013 decreased by approximately 35% to $27.6 million from $42.2 million for the same period in 2012. Operating loss for the nine months ended September 30, 2013 was $27.5 million, which included $0.6 million in non-cash stock-based compensation expense, as compared with an operating loss of $42.0 million, including $2.9 million in non-cash stock-based compensation expense, in the year ago period.

Delcath raised approximately $23.2 million before related expenses through the Company's At-the-Market (ATM) equity offering program during the nine months ended September 30, 2013, including approximately $2.3 million in the third quarter. As of October 31, 2013, there was approximately $47 million available under the ATM program.  In addition, the Company raised $9.0 million before related expenses through its Committed Equity Financing Facility (CEFF) program during the nine months ended September 30, 2013.  At September 30, 2013, there was approximately $24 million available under the CEFF program.

Cash and cash equivalents as of September 30, 2013 were $27.7 million, compared with $23.7 million at December 31, 2012. Combined with October financing activities, pro forma cash and cash equivalents were approximately $35 million.  During the nine months ended September 30, 2013, cash used in operating activities was $28.9 million, a 29% reduction compared to $40.7 million in the comparable nine month period in 2012. The decrease in cash utilization was in part due to a reduction in NDA submission-related costs, and improved organizational and operational efficiencies.

With the recently announced reorganization, management believes the Company is on track to meet previously established guidance of $6-7 million cash burn in the fourth quarter of 2013 and a quarterly average cash burn projection of $5-6 million in 2014. The Company will continue to examine additional cost effectiveness strategies, while focusing resources on clinical adoption and corporate development programs.

Conference Call and Webcast

The Company will host a conference call today, November 6, 2013 at 4:30 p.m. ET. The dial-in numbers for the conference call are 800-706-7745 (U.S. participants) and 617-614-3472 (international participants); both numbers require passcode 38516673. To access the live webcast, go to the Events & Presentations page on the Investor Relations section of the Company's website at http://www.delcath.com/investors/events

A taped replay of the call will be available beginning approximately two hours after the call's conclusion and will be available for seven days. Dial-in numbers for the replay are 888-286-8010 and 617-801-6888 for U.S. and International callers, respectively. The replay passcode for both U.S. and International callers is 31858222. An archived webcast will also be available at http://www.delcath.com/investors/events

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary drug/device combination product, the Delcath Hepatic Delivery System, is designed to administer high dose chemotherapy and other therapeutic agents to the liver, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. Outside of the United States, our proprietary product to deliver and filter melphalan hydrochloride is marketed under the trade name Delcath Hepatic CHEMOSAT® Delivery System for melphalan hydrochloride. The Company obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT Delivery System for Melphalan in April 2012. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT Delivery System for Melphalan in Europe. The Delcath Hepatic Delivery System for Melphalan has not been approved for sale in the United States by the United States Food and Drug Administration.  The Company has initiated plans to investigate Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System for primary liver cancer.

Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: efficiencies and reduction in cash utilization achieved through September 2013 staff reductions,  the leadership transition plan and its impact on the Company, the timing and results of future clinical trials including without limitation the HCC trials, clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in Europe, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets, the Company's ability to satisfy the  requirements of the FDA's Complete Response Letter and  provide the same in a timely manner, approval of the current or future chemosaturation system for delivery and filtration of melphalan, doxorubicin or other chemotherapeutic agents for various indications in the US and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, our ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the  timing and revenue, if any, of the same, uncertainties relating to the timing and results of research and development projects,, and uncertainties regarding our ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Contact Information:


Investor Contact: 

Media Contact:

Michael Polyviou/Patty Eisenhaur 

John Carter

EVC Group 

EVC Group

212-850-6020/951-316-0577 

212-850-6021

 

DELCATH SYSTEMS, INC.

Condensed Consolidated Balance Sheets

as of September 30, 2013 and December 31, 2012

(Unaudited)

(in thousands, except share data)















 September 30, 



 December 31, 






2013



2012

Assets:








Current assets







Cash and cash equivalents

$

27,735


$

23,726


Accounts receivables


111



144


Inventories, net


963



1,105


Prepaid expenses and other current assets


1,200



1,457



Total current assets


30,009



26,432


Property, plant and equipment, net


3,293



4,042



Total assets


$

33,302


$

30,474










Liabilities and Stockholders' Equity:






Current liabilities







Accounts payable

$

684


$

939


Accrued expenses



3,375



5,790


Warrant liability


863



3,427



Total current liabilities


4,922



10,156










Long Term Liabilities








Deferred revenue



7



309


Accrued expenses



490



-



Total long term liabilities


497



309







Commitments and contingencies


-



-










Stockholders' equity







Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2013 and December 31, 2012


-



-


Common stock, $.01 par value; 170,000,000 shares authorized; 103,318,021 and 76,849,033 shares issued and 103,289,921 and 76,820,933 shares outstanding at September 30, 2013 and December 31, 2012, respectively


 

1,033



 

768


Additional paid-in capital


250,821



218,063


Accumulated deficit


(224,341)



(198,808)


Treasury stock, at cost; 28,100 shares at September 30, 2013 and December 31, 2012


(51)



(51)


Accumulated other comprehensive income


421



37



Total stockholders' equity


27,883



20,009



Total liabilities and stockholders' equity

$

33,302


$

30,474










 

 

Delcath Systems, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

for the three and nine months ended September 30, 2013 and 2012

(Unaudited)

(in thousands, except share data)
















Three months ended September 30,


Nine Months Ended September 30,



2013


2012


2013


2012

Product revenue

$

72


$

39


$

152


$

146

Other revenues


-



-



300



-

Total revenue


72



39



452



146

Cost of goods sold


(23)



-



(386)



-

Gross profit


49



39



66



146














Operating expenses:













Selling, general and administrative1

$

4,573


$

6,960


$

16,919


$

21,604


Research and development1


2,178



5,254



10,639



20,589

Total operating expenses


6,751



12,214



27,558



42,193

Operating loss


(6,702)



(12,175)



(27,492)



(42,047)

Change in fair value of warrant liability, net


(497)



446



2,345



1,025

Interest income


2



9



18



16

Other expense and interest expense


(9)



(93)



(404)



(204)

Net loss

$

(7,206)


$

(11,813)


$

(25,533)


$

(41,210)

Common share data:













Basic and diluted loss per share

$

(0.07)


$

(0.18)


$

(0.27)


$

(0.72)














Weighted average number of basic and diluted common shares outstanding


100,068,998



67,219,224



94,023,834



56,844,697














Other comprehensive income (loss):













Foreign currency translation adjustments

$

15


$

87


$

384


$

83

Comprehensive loss

$

(7,191)


$

(11,726)


$

(25,149)


$

(41,127)















Note 1:













Includes non-cash stock-based compensation as follows:














 Three months ended September 30, 


 Nine Months Ended September 30, 



2013


2012


2013


2012


Selling, general and administrative

$

(159)


$

665


$

370


$

1,828


Research and development


(67)



372



217



1,094


Total stock-based compensation expense

$

(225)


$

1,073


$

587


$

2,922














 

SOURCE Delcath Systems, Inc.

Add a Comment

News   More...

Securities related to this article
Delcath Systems, Inc. View dcth Stock Quote
 
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Content Partners
Morningstar - 2013/11/6 - Delcath Reports 2013 Third Quarter Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Author |  Collection |  Interest |  Popularity

Previous: Delcath Reports 2013 Fourth Quarter And Full Year Results  |  Next: Delek Group Announces Consolidated Full Year Results 2013